uniQure (NASDAQ:QURE) Shares Down 9.2% – What’s Next?

uniQure N.V. (NASDAQ:QURE) traded down 9.2% during mid-day trading on Monday . The company traded as low as $23.23 and last traded at $22.9860. 369,864 shares were traded during trading, a decline of 78% from the average session volume of 1,691,101 shares. The stock had previously closed at $25.32.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. UBS Group set a $95.00 target price on uniQure in a research note on Thursday, September 25th. Royal Bank Of Canada decreased their price target on shares of uniQure from $65.00 to $45.00 and set an “outperform” rating for the company in a report on Monday, November 3rd. The Goldman Sachs Group lowered their target price on uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. Wells Fargo & Company dropped their price objective on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, November 12th. Finally, Stifel Nicolaus lowered their target price on uniQure from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, December 11th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.82.

uniQure Trading Down 9.0%

The stock has a market capitalization of $1.44 billion, a P/E ratio of -5.25 and a beta of 0.68. The business has a 50 day simple moving average of $25.46 and a 200-day simple moving average of $27.61. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12.

uniQure (NASDAQ:QURE) last announced its earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $4.46 million. uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. On average, analysts predict that uniQure N.V. will post -3.75 EPS for the current year.

Insider Buying and Selling at uniQure

In related news, Director Robert Gut sold 31,434 shares of uniQure stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $27.26, for a total value of $856,890.84. Following the transaction, the director owned 40,145 shares of the company’s stock, valued at approximately $1,094,352.70. This trade represents a 43.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jack Kaye sold 38,810 shares of the business’s stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total value of $1,177,495.40. Following the sale, the director owned 20,439 shares in the company, valued at approximately $620,119.26. The trade was a 65.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 4.79% of the company’s stock.

Hedge Funds Weigh In On uniQure

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Private Trust Co. NA acquired a new stake in shares of uniQure in the third quarter worth $28,000. Jones Financial Companies Lllp lifted its stake in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC acquired a new stake in uniQure during the 3rd quarter worth about $50,000. FNY Investment Advisers LLC grew its stake in uniQure by 76.7% during the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 718 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 5,538 shares in the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.